SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

About Cartesi (CTSI)  Cartesi enables developers to build appchain rollups with any code, while benefiting from the security of Ethereum. It bridges the gap between traditional software and blockchain by bringing decades of mature operating systems, programming languages, libraries, and tools to decentralized applications.  Cartesi aims to provide the technological foundation from which builders, entrepreneurs, and projects will develop decentralized applications. The Cartesi technology suite is currently comprised of:  Cartesi Rollups: Cartesi Rollups is an app-specific execution environment that can be deployed as a L2, L3, or as sovereign rollups. The combination of an Optimistic Rollups framework and the Cartesi Machine Emulator enables the development of smart contracts and dApps using any package or library that is available for Linux. This allows developers to break free from the scalability limitations of the Ethereum Virtual Machine (EVM), and brings the rise of a new blockchain era to handle real-life and complex use cases.  Cartesi Machine: A RISC-V-based virtual machine (altVM) running Linux OS, enabling complex computations and seamless dApp development by expanding the design space and leveraging 40 years of software programming advancements.  CartesiScan: Cartesiscan is the explorer used for viewing blockchain transactions on Cartesi appchain rollups.  Cartesi Explorer: The Cartesi Explorer is a product that allows CTSI users to interact with the governance system and stake CTSI.  Fraud Proof System - DAVE (following PRT): Dave is a permissionless, interactive fraud-proof system. Cartesi’s algorithm further optimizes the fraud proof mechanism to achieve the best balance between security, decentralization, and activity.  What Makes Cartesi Unique  The infrastructure of the internet took 40 years, billions of hours of work, and trillions of dollars to build. With Cartesi, developers gain access to these decades of meticulously refined operating systems, programming languages, software libraries, and tools, paving the way for the next generation of blockchain applications.  Cartesi empowers Ethereum rollups with real-world software and strong guarantees.  Cartesi designed its own Optimistic Rollups framework embedding its own non-EVM virtual machine based on RISC-V.  Leverage decades‑proven software ecosystems: The Cartesi Machine enables full Linux and RISC‑V stack execution in a composable, verifiable rollup environment.  Cartesi’s architecture is optimized for app‑specific rollups, providing scalable and secure chains tailored to each dApp’s needs, backed by a state-of-the-art fraud proof system, properly categorized as Stage-2 according to L2BEAT.  Token Utility  Governance: CTSI holders can currently stake their tokens to earn rewards and participate in ecosystem governance.   Validator Marketplace: Applications built on Cartesi need validators to monitor and ensure the trustworthiness of transactions. The Validator Marketplace is a decentralized matchmaking service that connects applications with validation service providers. The Validator Marketplace will leverage the CTSI token as a primary means of incentivization in three important ways:  1. Validators will be required to stake CTSI in order to participate, ensuring performance and honest behavior.  2. CTSI holders will be able to delegate their CTSI to experienced validators, allowing tokenholders to share in validation fees without running their own nodes.  3. Token holders can use their CTSI to “buy” a stake in a dApp’s future growth, signaling support for dApps they believe will succeed. The earlier a backer “gets in” on a dApp, the more they are rewarded as that dApp gains traction.  The Validator Marketplace creates a direct link between Cartesi dApp usage and CTSI token demand, enabling token holders to share in the growth and success of the ecosystem.

Cartesi

Cartesi is trending as the community anticipates a potential breakout, citing improving technicals and increasing volume. Some believe it's primed for significant gains, drawing comparisons to other successful Layer-2 solutions and highlighting its strong fundamentals. The community is also actively discussing its potential within the broader altcoin season.

Pump.fun

$PUMP.X is trending as traders discuss its potential as a 'pick and shovel' play within the memecoin ecosystem, with fees from the Pump.fun platform driving value back to the token. The community highlights the platform's utility and ease of use, while also debating its potential to disrupt streaming services. Some users are expressing confidence in significant gains, while others caution about the risks associated with meme coins.

Shido

Shido is trending due to ongoing developments surrounding its ecosystem, including the imminent launch of its mainnet and associated tools like the Shido IDE and Shidoscan V2. The community is focused on Shido's features, such as its dual-VM architecture and planned DeFi services, with anticipation building around potential CEX listings and partnerships that could further expand the network's reach.

"What's Updog?" is a Community Led token.

UpDog

UpDog ($UPDOG.X) is trending as the community rallies around this Solana-based meme coin, emphasizing its commitment to donating to animal shelters. Community members are actively congratulating other trending tokens for being "UpDog", highlighting the coin's growing presence and positive sentiment. The coin's solid fundamentals, joke-inspired meta, and listing on Jupiter Exchange are also being discussed as drivers of its potential.

Flare is a blockchain for building applications that are interoperable with other blockchains and the internet.  ## What is Flare (FLR)?  Flare is an EVM-based Layer 1 blockchain designed to allow developers to build applications that are interoperable with blockchains and the internet. By providing decentralized access to high-integrity data, Flare enables new use cases and monetisation models.   ## What makes Flare unique?  Flare's native interoperability protocols, the State Connector and the FTSO are secured by the network itself, allowing it to reliably deliver data from a wide variety of off-chain sources in a decentralized way.   The Flare Time Series Oracle delivers highly-decentralized price and data feeds to dapps on Flare, without relying on centralized providers.   The State Connector protocols enable information, both from other blockchains and the internet to be used securely, scalably and trustlessly with smart contracts on Flare.  Risk is minimized by building this decentralized data infrastructure natively into the blockchain, powered by a large number of independent data providers.  By incentivizing sets of independent providers to query, acquire, and process data without relying on single, centralized sources, Flare’s core protocols can facilitate the development of interoperable dapps with a broad range of potential innovative use cases.   ## What is the Flare (FLR) token used for?  FLR is the native token used for payments, transaction fees to prevent spam attacks and staking in validator nodes. FLR can also be wrapped into an ERC-20 variant, WFLR. WFLR tokens serve various functions; they can be delegated to FTSO data providers, for example, or staked to participate in governance. These two uses are not mutually exclusive and do not prevent the tokens from being used in other EVM-compatible dapps and smart contracts on Flare.  Wrapped FLR (WFLR) can be minted by depositing native FLR tokens into a smart contract and withdrawing the newly minted

Spark Token

Spark Token ($FLR.X) is trending as community members discuss its potential within the XRP ecosystem and its possible integration with staking platforms. The recent buzz is fueled by news of adoption headlines and staking rewards via monthly airdrops. Some investors are optimistic about its long-term growth, drawing comparisons to other successful tokens and anticipating a significant rise in value.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF ($DAX) is trending as the index flirts with all-time highs, driven by optimism around potential shifts in German economic policy and a possible resolution to the conflict in Ukraine. Community members are actively discussing technical indicators and potential entry points, while also considering broader economic factors and the potential for a pullback.

Direxion Shares ETF Trust - Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

GUSH is trending as traders discuss oil price forecasts, support and resistance levels, and potential trading strategies. Community members are sharing technical analysis, potential entry points, and discussing the impact of geopolitical tensions on oil prices. Some traders express frustration with GUSH's performance relative to oil prices, while others remain optimistic due to potential dividends and seasonal trends.

Dolomite

Dolomite is gaining attention as community members speculate on potential significant gains and draw comparisons to past successes of similar tokens. Conversations mention a possible connection to another crypto, while some suggest it is undervalued and poised for a breakout during altcoin season. The community is actively encouraging others to take notice of this trending cryptocurrency.

BlackBerry Ltd

BlackBerry is trending as investors discuss its potential turnaround, highlighting key partnerships and the growing adoption of QNX in safety-critical systems. Community members are pointing to upcoming earnings as a possible catalyst, with some expressing optimism about revenue growth and margin expansion. The discussion also includes speculation around potential acquisitions and strategic moves, particularly related to its QNX and cybersecurity divisions.

BONE SHIBASWAP

$BONE.X is trending as the Shibarium network addresses a recent flash loan attack, sparking community discussion about security and validator protocols.  Staking and reward opportunities within the Shiba Inu ecosystem, particularly with K9 Finance ($KNINE.X), are also a central focus, with users exploring DeFi options like liquid staking and liquidity pool farming. Community members are actively debating the health and future direction of the entire Shiba Inu ecosystem and its tokens.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of BioLineRx (BLRX) skyrocketed 32% on Friday after the biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-new-pilot-phase-data-phase-2-combination">announced</a> positive data from the single-arm pilot phase of its Phase 2 trial evaluating its drug in the treatment of pancreatic cancer.The study is evaluating the company’s Motixafortide, Cemiplimab, and standard-of-care chemotherapies Gemcitabine and Nab-paclitaxel, versus Gemcitabine and Nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year. Progression-free means that the patient's disease did not get worse or spread.CEO Philip Serlin said that the data emerging from the pilot phase of the study are “extremely encouraging,” while also noting that pancreatic cancer is the “most challenging” tumor to treat.The company also stated that it now plans to enroll 108 patients in the Phase 2 trial, which will be a randomized study, based on the results of the pilot phase. The company had previously planned to enroll only 30 patients in the study.The trial is planned to be fully enrolled in 2027. While the trial's primary endpoint is progression-free survival (PFS), secondary objectives include safety, response rate, disease control rate, duration of clinical benefit, and overall survival.Following the news, Jones Research upgraded BioLineRx to ‘Buy’ from ‘Hold’ with a $12 price target. With these results, BioLineRx will have additional opportunities to either partner the asset or fund a pivotal trial, assuming favorable Phase II results, the analyst said.On Stocktwits, retail sentiment around BLRX jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_12_47_05_PM_png_ca2195fcbe.webp" alt="BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits" width="626" height="68"><figcaption>BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/BLRX">BLRX</a> is down by about 50% this year and by about 84% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gilead-eyeing-hiv-drug-rollout-in-low-income-countries-report/ch0ubVvRbuE">Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating

The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year.

Equity

Nasdaq-listed shares of BioLineRx (BLRX) traded 4% higher on Tuesday afternoon after the company reported an over 600% year-on-year jump in its first-quarter net income.The Israel-based biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2025-financial-results-and-provides-corporate-update-302465635.html">reported</a> revenues for the three months ended March 31, 2025, of $0.3 million, compared to revenues of $6.9 million in the year-ago period, and below an analyst estimate of $1 million, as per Koyfin data.BioLineRx out-licensed its FDA-approved Aphexda, used in treating a type of cancer called multiple myeloma, to Ayrmid last November and shut its U.S. commercial operations by the year-end.Aphexda, however, generated sales of $1.4 million in the first quarter, providing the company with $0.3 million in royalties.The fall in revenue in the first quarter reflects the company’s change in operation after out-licensing Aphexda, it said.Net income for the quarter ended March 31, 2025, was $5.1 million, compared to $0.7 million for the quarter ended March 31, 2024, and above an estimated net loss of $3 million. The net non-operating income stood at $7.6 million, compared to net non-operating income of $4.5 million in the three months ended March 31, 2024.The company ended the quarter with cash, cash equivalents, and short-term bank deposits of $26.4 million, which it expects to be sufficient through the second half of 2026.CEO Philip Serlin said that the company has been actively evaluating new assets in the areas of oncology and rare diseases, where it can leverage its expertise after out-licensing Aphexda."I remain optimistic that we will announce a meaningful transaction this year," he said.On Stocktwits, retail sentiment around BioLineRx rose within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_27_at_1_49_08_PM_png_c44b3d7c0e.webp" alt="BLRX's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 27, 2025 | Source: Stocktwits " width="627" height="65"><figcaption>BLRX's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 27, 2025 | Source: Stocktwits&nbsp;</figcaption></figure><a href="https://stocktwits.com/symbol/BLRX">BLRX stock</a> is down by about 63% this year and nearly 87% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/byd-sued-by-brazil-prosecutors-for-alleged-human-trafficking/ch0V1GJRbra">BYD Sued By Brazil Prosecutors For Alleged Human Trafficking: Retail’s In Wait-And-Watch Mode</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident

CEO Philip Serlin said that the company has been actively evaluating new assets in the areas of oncology and rare diseases, where it can leverage its expertise after out-licensing Aphexda. 

BioLineRx Issues Letter to Shareholders

BioLineRx Issues Letter to Shareholders BioLineRx Issues Letter to Shareholders PR Newswire TEL AVIV, Israel, Jan. 21, 2025 - Company outlines strategic long-term vision and financial outlook - TEL...

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares PR Newswire TEL AVIV, Israel...

BioLineRx Announces $10 Million Registered Direct Offering

BioLineRx Announces $10 Million Registered Direct Offering BioLineRx Announces $10 Million Registered Direct Offering PR Newswire TEL AVIV, Israel, Jan. 6, 2025 TEL AVIV, Israel, Jan. 6, 2025...

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on...

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell...

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA (motixafortide) through Gamida Cell Ltd.

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA (motixafortide) through Gamida Cell Ltd. BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to...

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 PR Newswire TEL AVIV, Israel, Nov. 20, 2024 Management to Hold...

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024...

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

BLRX
BioLineRx, Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BLRX News

BLRX BioLineRx, Ltd.